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ObituaryJanet Davison Rowley (1925–2013)The scientific community has lost one
of its giants, whose work laid the founda-
tion for modern cancer genetic research
and a new paradigm for precision
oncology, namely targeted therapy.
The rest of the world has lost an extra-
ordinary spirit who, as a mentor, mother,
colleague, friend, and humanitarian
inspired those around her to be better.
Janet D. Rowley, M.D., died on December
17, 2013, from complications of ovarian
cancer. Speaking about her own cancer
experience as recently as November
when she accepted an award from the
University of Chicago Cancer Research
Foundation, Janet said, ‘‘Cancer can be
cured if we work hard enough.’’ It wasJanet Rowleythat type of resolve and
commitment that dictated
her work and every other facet
of her life.
Janet was born April 5,
1925, in New York City, but
before her second birthday,
her family moved to Chicago,
where she would live for
most of her life. At only 15,
she earned a scholarship
to begin coursework at the
University of Chicago. At
19 years of age, she applied
to medical school at the
University of Chicago, but
was forced to delay a year
because the quota for women
(three) that year was filled.
Janet married one of her
classmates, Donald A. Row-
ley, M.D., the day after medi-
cal school graduation. When
Janet worked as a physician
at a clinic for children with
mental retardation in Chicago,
she was first exposed to cyto-
genetics and the astounding
discovery that Down syn-
drome was the result of three
copies of chromosome 21.
When Don accepted a sab-
batical appointment in Ox-
ford, England in 1961, Janet
secured a special post-
doctoral fellowship from the
National Institutes of Health
and turned to Marco Fraccaroat the Medical Research Council Unit
on Genetics in Headington, Oxford, to
learn cytogenetics. It was then that
she recalled cutting out the photo-
graphed chromosomes from metaphase
cells, placing them on the dining room
table, and ensuring that her young boys
did not cough, sneeze, or otherwise
disturb her carefully arranged karyotypes.
This work catalyzed Janet’s passion for
research, so much so that she decided
not to return to the clinic. It also allowed
her to have a flexible schedule to raise
her boys.
Upon returning to Chicago in 1962, she
negotiated with Dr. Leon O. Jacobson, a
hematologist at the University of Chicago,Cancer Cellto use a photomicroscope and 3 ft of
bench space to establish her research
program on a part-time basis. She began
to analyze the karyotypes of some of
Dr. Jacobson’s patients and published
a paper describing chromosome abnor-
malities in preleukemia. She later learned
chromosome banding upon a return
visit to Oxford in 1970. At that time,
many hematologists and other scientists
were not convinced about the impor-
tance of chromosome abnormalities,
especially translocations, essentially con-
verting Janet into an early ‘‘crusader for
cytogenetics.’’
Early in 1972, she studied the cells of a
patient with acute myeloid leukemia25, January(AML) and identified a chro-
mosome abnormality as a
reciprocal translocation be-
tween chromosomes 8 and
21. At that time, she also had
data that the Philadelphia
chromosome (Ph), originally
described in 1960 as a
small deleted chromosome
by Nowell and Hungerford,
might be a translocation as
well. In June 1973, Janet
published the landmark
paper that described the
finding of a translocation
between the long arms of
chromosomes 9 and 22 in
bone marrow cells from each
of nine consecutive patients
with chronic myelogenous
leukemia (CML). The chro-
mosomal translocations that
Janet discovered in AML
and CML are the first two
recurring translocations in
any human cancer; she went
on to identify many other
recurring abnormalities.
A decade later, as cellular
oncogenes were cloned and
mapped to human chro-
mosomes, Janet recognized
that their chromosome loca-
tion correlated with the
breakpoints of the recurring
translocations, and she pro-
posed that the function
of cellular oncogenes was13, 2014 ª2014 Elsevier Inc. 1
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Obituaryaltered as a result of chromosomal
abnormalities, leading to uncontrolled
proliferation. Over the ensuing years,
many translocation breakpoints were
cloned and the involved oncogenes were
identified, thus ending her decades-long
crusade to convince other physicians
and scientists that chromosomal abnor-
malities in tumors were more than
irrelevant epiphenomena that occurred
as a result, rather than the cause, of the
malignant phenotype.
One of Janet’s greatest legacies is
that she helped promote the under-
standing that cancer is not one disease,
but many. Decades before the era of
genomic profiling, her work, and that
of her colleagues, led to the recogni-
tion that chromosome abnormalities
were associated with distinct subtypes
of leukemia and lymphoma and had
prognostic significance. ‘‘Janet Rowley’s
work established that cancer is a
genetic disease,’’ said Mary-Claire King,
professor of genome sciences and
medicine at the University of Washington
School of Medicine. ‘‘She demonstrated
that mutations in critical genes lead
to specific forms of leukemia and lym-
phoma and that one can determine
the form of cancer present in a patient
directly from the genetic changes in the
cancer. We are still working from her
paradigm.’’
It was Janet’s early work on the t(9;22)
in CML that has culminated in the most
successful example of targeted therapy
to date—an approach that has revolution-
ized how genetic profiles of tumors are
utilized in clinical care. Although it took
many years after the breakpoint wasmap-
ped and the BCR-ABL1 fusion was identi-
fied, Imatinib, as well as second- and
third-generation ABL1 tyrosine kinase in-
hibitors, have become standard therapy
for patients with newly diagnosed CML,
thereby changing the natural history of
this disease.2 Cancer Cell 25, January 13, 2014 ª2014 ElTo elucidate how other translocations
drove the cancer phenotype, Janet’s
group cloned a number of translocation
breakpoints. Further, her laboratory
cloned the gene at the breakpoint of
the common translocations of 11q23
that she called MLL, for myeloid-
lymphoid leukemia (now known as
KMT2A). This work resulted in the
cloning of almost 75 MLL translocation
partner genes, molecular detection of
MLL leukemias, and, ultimately, the
emergence of research on lysine methy-
ltransferases in cancer. True to the spirit
of innovation, Janet turned her attention
in later years to defining the biological
features of human leukemia by gene
and microRNA expression profiling. To
facilitate all of this work, as well as that
of her colleagues around the globe, she
organized a series of International Work-
shops that provided the clinical data and
cytogenetic expertise to transform and
advance the field of cancer genetics.
We recently celebrated the 40th anni-
versary of her key discovery of recurr-
ing translocations, and she has been
acknowledged for her contributions with
some of the most prestigious award in
biomedical research, including, in 2009,
the Presidential Medal of Freedom. At
that ceremony, President Obama noted,
‘‘All of us have been touched in some
way by cancer, including my family—and
so we can all be thankful that what began
as a hobby became a life’s work for
Janet.’’
Janet’s passion for her hobby and
life’s work was infectious, and she gladly
passed it along to the countless scientists
and cytogeneticists whom she mentored
and trained, including one of the authors
(M.M.L.). She was especially supportive
of female physicians and scientists and
served as a role model for those who fol-
lowed in her footsteps. She was
extremely proud of raising her family,
and she often commented on how shesevier Inc.did not do anything very remarkable in
her career until well into her 40s. Likewise,
she attributed her accomplishments to
good luck and timing. Clearly, humility
and graciousness were qualities ascribed
to Janet. She once said, ‘‘Looking down a
microscope at banded chromosomes is
not rocket science. If I had not found it,
someone else would have.’’ Perhaps
that is true, but it was Janet’s persever-
ance, her attention to detail, and some
serendipity that secured her place in
cancer research history. In recent years,
she was also a vocal advocate for
biomedical research, serving on the Pres-
ident’s Council on Bioethics and National
Cancer Legislation Advisory Committee.
She was concerned that the type of
work that she did, so called ‘‘observa-
tion-driven research,’’ did not have a
place in the ‘‘hypothesis-driven’’ science
that is currently funded. Janet was also
certain that the type of success that she
had in her illustrious career would not
have been possible today, underscoring
her view that scientists need support,
freedom, and creativity to address the
critical questions.
Janet Rowley’s career and legion of
trainees are her enduring legacy to her
belief that the ultimate goal of research
is to benefit patients and improve human
life. She leaves behind a scientific com-
munity and colleagues that will sorely
miss her enthusiasm and passion for sci-
entific advancement. Janet is survived
by three of her four sons, who also lost
their father Don last year, and five
grandchildren.
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